These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

988 related items for PubMed ID: 17205957

  • 1. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [Abstract] [Full Text] [Related]

  • 2. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R, Jaroszewicz J, Lapiński TW, Flisiak I, Rogalska M, Prokopowicz D.
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [Abstract] [Full Text] [Related]

  • 3. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
    Yang K, Palm J, König J, Seeland U, Rosenkranz S, Feiden W, Rübe C, Rübe CE.
    Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
    [Abstract] [Full Text] [Related]

  • 4. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ, Sellers RG, Wiehr C, Melamud O, Pei D, Peehl DM.
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [Abstract] [Full Text] [Related]

  • 5. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP, Molenaar IQ, Verspaget HW, Veldman MG, Palareti G, Legnani C, Moolenburgh SE, Terpstra OT, Lamers CB, van Hoek B, Porte RJ.
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [Abstract] [Full Text] [Related]

  • 6. Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies.
    Zakiyanov O, Kalousová M, Kratochvilová M, Kríha V, Zima T, Tesar V.
    J Nephrol; 2013 Mar; 26(3):502-9. PubMed ID: 22760877
    [Abstract] [Full Text] [Related]

  • 7. [Influence of recombinant transforming growth factor-beta3 on collagen synthesis and deposition: experiment with rat cell model of liver fibrosis].
    Li Q, Zhou X, Yu J, Qian W, Xu KS.
    Zhonghua Yi Xue Za Zhi; 2008 May 13; 88(18):1273-8. PubMed ID: 18844103
    [Abstract] [Full Text] [Related]

  • 8. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
    Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR.
    Nephrol Dial Transplant; 2006 Sep 13; 21(9):2406-16. PubMed ID: 16728425
    [Abstract] [Full Text] [Related]

  • 9. Role of platelet-derived growth factor and transforming growth factor beta1 the in the regulation of metalloproteinase expressions.
    Borrelli V, di Marzo L, Sapienza P, Colasanti M, Moroni E, Cavallaro A.
    Surgery; 2006 Sep 13; 140(3):454-63. PubMed ID: 16934609
    [Abstract] [Full Text] [Related]

  • 10. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis.
    Sanders JS, van Goor H, Hanemaaijer R, Kallenberg CG, Stegeman CA.
    Nephrol Dial Transplant; 2004 Jun 13; 19(6):1412-9. PubMed ID: 15034162
    [Abstract] [Full Text] [Related]

  • 11. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
    Ergul A, Portik-Dobos V, Hutchinson J, Franco J, Anstadt MP.
    Am J Hypertens; 2004 Sep 13; 17(9):775-82. PubMed ID: 15363819
    [Abstract] [Full Text] [Related]

  • 12. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
    Chen RQ, Chen XM, Cui SW, Cai GY, Shi SZ, Xie YS, Lu Y, Peng LX.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 02; 84(11):937-42. PubMed ID: 15329283
    [Abstract] [Full Text] [Related]

  • 13. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration.
    Fujiwara M, Muragaki Y, Ooshima A.
    Br J Dermatol; 2005 Aug 02; 153(2):295-300. PubMed ID: 16086739
    [Abstract] [Full Text] [Related]

  • 14. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R.
    J Pharmacol Exp Ther; 2006 Jan 02; 316(1):8-16. PubMed ID: 16166267
    [Abstract] [Full Text] [Related]

  • 15. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM, Novaes AB, Meschiari CA, Souza SL, Palioto DB, Sorgi CA, Faccioli LH, Tanus-Santos JE, Gerlach RF.
    Clin Chim Acta; 2009 Nov 02; 409(1-2):117-22. PubMed ID: 19751716
    [Abstract] [Full Text] [Related]

  • 16. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM, Gerlach RF, Tanus-Santos JE.
    Clin Chim Acta; 2009 May 02; 403(1-2):173-7. PubMed ID: 19254704
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of matrix metalloproteinase on hepatic transforming growth factor beta1 and caspase-3 activation in hemorrhage.
    Maitra SR, Bhaduri S, El-Maghrabi MR, Shapiro MJ.
    Acad Emerg Med; 2005 Sep 02; 12(9):797-803. PubMed ID: 16141011
    [Abstract] [Full Text] [Related]

  • 18. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z.
    J Nephrol; 2007 Sep 02; 20(4):444-52. PubMed ID: 17879211
    [Abstract] [Full Text] [Related]

  • 19. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE.
    Ann Rheum Dis; 2001 Sep 02; 60(9):846-51. PubMed ID: 11502611
    [Abstract] [Full Text] [Related]

  • 20. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
    Pancewicz SA, Izycka A, Klibingat M, Zajkowska JM, Swierzbińska-Pijanowska R, Kondrusik M, Grygorczuk SS, Izycki T, Hermanowska-Szpakowicz T.
    Pol Merkur Lekarski; 2008 Dec 02; 25(150):495-9. PubMed ID: 19205380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.